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Abstract
We previously showed that HIV-1 subtype C viruses elicit potent but highly type-specific neutralizing antibodies (nAb)
within the first year of infection. In order to determine the specificity and evolution of these autologous nAbs, we examined
neutralization escape in four individuals whose responses against the earliest envelope differed in magnitude and potency.
Neutralization escape occurred in all participants, with later viruses showing decreased sensitivity to contemporaneous sera,
although they retained sensitivity to new nAb responses. Early nAb responses were very restricted, occurring sequentially
and targeting only two regions of the envelope. In V1V2, limited amino acid changes often involving indels or glycans,
mediated partial or complete escape, with nAbs targeting the V1V2 region directly in 2 cases. The alpha-2 helix of C3 was
also a nAb target, with neutralization escape associated with changes to positively charged residues. In one individual,
relatively high titers of anti-C3 nAbs were required to drive genetic escape, taking up to 7 weeks for the resistant variant to
predominate. Thereafter titers waned but were still measurable. Development of this single anti-C3 nAb specificity was
associated with a 7-fold drop in HIV-1 viral load and a 4-fold rebound as the escape mutation emerged. Overall, our data
suggest the development of a very limited number of neutralizing antibody specificities during the early stages of HIV-1
subtype C infection, with temporal fluctuations in specificities as escape occurs. While the mechanism of neutralization
escape appears to vary between individuals, the involvement of limited regions suggests there might be common
vulnerabilities in the HIV-1 subtype C transmitted envelope.
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Introduction
Neutralizing antibody (nAb) responses which target the Env of
HIV-1 and block viral entry develop in most HIV-1 infected
individuals, reaching detectable levels within a few months of
infection when measured against the autologous Env [1,2,3,4].
Much of the variation that occurs in the Env during early infection is
thought to be the result of pressure exerted by autologous nAbs,
which is testimony to the potency of such responses [3,4,5].
Neutralization escape has been documented in HIV-1 subtype B
viruses [3,4,6,7,8,9,10,11,12] and in SIV [13,14,15] with contem-
poraneous viruses showing less sensitivity to autologous neutraliza-
tion than earlier viruses. Even in virus controllers with relatively low
levels of antigenic stimulation of B cells, continuous viral selection
and escape from autologous nAbs occurs [16]. However, the
dynamic nature of the autologous neutralizing response is exempli-
fied by the fact that escape variants are sensitive to de novo nAb
responses generated to new variants. The nature and timing of the
novel responses, or whether initial autologous nAbs are maintained
or decay is not clear. It seems likely that early nAbs will wane as
escape occurs, when the antigen responsible for elicitation of such
responsesisreplacedbyescape variants,whichwouldpresumablyno
longer stimulate existing antigen-specific B cells.
Escape from autologous nAbs may occur through amino acid
substitutions resulting in mutational variation at epitopes [17],
insertions and deletions (indels) in the Env [18,19], and through an
‘‘evolving glycan shield’’, where a shift in the number and position
of glycans prevents access of nAbs to their cognate epitopes
[4,19,20]. The relative importance of each mechanism of escape is
not clear, and in many cases, a global view of envelope mutations
and indels in escaped variants has not allowed precise elucidation
of the genetic basis of escape [3,12,17]. Furthermore, the
specificities, number and kinetics of the antibodies driving escape
are largely unknown.
The autologous nAb response in subtype C infection appears to
differ somewhat from that in subtype B viruses and is less well-
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titer and are particularly type-specific with little or no cross-
neutralizing activity within the first year of infection [1,2]. The
type-specificity of autologous nAbs implies that they target variable
regions, and indeed we have shown that nAbs directed at the
V1V2, V4 and V5 regions contributed to autologous neutraliza-
tion in some HIV-1 subtype C infected individuals [1,21].
The role of V1V2 in shielding neutralization determinants is
well-recognized [19,20,22,23,24,25,26]. V1V2 may also act as a
neutralization target in some laboratory adapted HIV isolates [27]
and primary HIV isolates [1,18,21,28,29,30,31,32,33]. Further-
more, use of reciprocal V1V2 chimeras suggested that the V1V2
region was principally responsible for the strain-specific AnAbs
detected in plasma from SHIV-infected monkeys [34]. In subtype
C, variable regions (V1 to V4) have also been implicated in
shielding neutralization determinants, and infection may be
mediated by viruses with relatively short variable loops and high
sensitivity to neutralization by donor sera [35]. The role of V4 and
V5 in neutralization resistance is less clear, although these regions
may impact on envelope conformation and glycan packing
[4,15,36], thereby sterically limiting accessibility of neutralization
determinants.
In addition to the variable regions, the C3 region, located in the
outer domain of gp120 slightly upstream of the V3 loop has been
implicated in neutralization escape in subtype C viruses [37]. The
C3 region of subtype C viruses is under strong diversifying
pressure [38] and there are distinct structural differences between
subtypes B and C in the alpha 2 (a2)-helix of C3 [37] suggesting
increased exposure of this region in subtype C viruses. It has
therefore been proposed that nAbs directly target the a2-helix in
subtype C viruses [37,39]. We recently showed that the region is a
major target of autologous neutralizing antibodies in subtype C
HIV-1 infection [21].
Here we investigated neutralization escape in 4 individuals from
the CAPRISA 002 Acute Infection cohort, including one virus
controller, 2 individuals classified as intermediate progressors, and
one rapid progressor. Neutralization profiles against the infecting
virus from three of the four individuals have been described
previously and were shown to differ in timing and magnitude
[1,21]. In this study, representative envelopes were derived by
single genome amplification (SGA) from multiple time points
during the first year of infection, and tested against autologous
plasma spanning the first 2 years of infection. We examined the
specificities of autologous nAbs using chimeric envelopes. Potential
escape mutations were identified by examination of sequences
from multiple time points, and tested by generating chimeric and/
or mutant envelopes representative of polymorphisms and
measuring the acquisition of neutralization sensitivity in resistant
envelope clones obtained at later time-points. Our data suggest
that antibodies targeting only one or two epitopes, predominantly
in V1V2 and C3, drive escape in some individuals in the first year
of infection in HIV-1 subtype C infection.
Results
Previously we have shown using the CAPRISA 002 Acute
Infection cohort that HIV-1 subtype C infection is characterized
by the appearance in the first year of potent and highly type-
specific neutralizing antibodies (nAbs) against the infecting virus
[1]. In order to determine if these antibodies exert immune
pressure we assessed later viruses for neutralization escape using
samples from 4 individuals who were selected based on their
disease profile, degree of genetic diversity and timing of the first
appearance of autologous nAbs (Table 1). We hypothesized that
individuals with increased genetic diversity were more likely to
have multiple antibody specificities forcing genetic escape.
Neutralization escape in early HIV-1 subtype C infection
CAP88, an intermediate progressor, first showed a neutralizing
response at 15 weeks p.i. [1]. Here we derived SGA envelope
Author Summary
Most HIV-1 infected individuals develop neutralizing
antibodies against their own virus, termed an autologous
neutralizing response. It is known that this response exerts
pressure on the envelope of HIV, the target of such
antibodies, resulting in neutralization escape. Here we
have identified the targets of these antibodies and the
precise genetic basis of neutralization escape in 4
individuals infected with HIV-1 subtype C. We show that
V1V2 is commonly involved in escape, and that the C3
region is also a target in some cases. The latter observation
confirms this region is exposed in subtype C, unlike
subtype B. We show that neutralization escape is conferred
by a few amino acid mutations, some of which are outside
the antibody target site. Moreover, escape from these
limited specificities even within a single individual occurs
via a variety of different pathways involving substitutions,
indels and glycan shifts. The finding in 2 individuals that an
anti-C3 response developed first, followed by an anti-V1V2
response, suggests there may be specific regions of
envelope particularly vulnerable to antibody neutraliza-
tion. Overall, we propose a mechanistic explanation for
how HIV-1 epitopes drive sequential waves of neutraliza-
tion escape in early subtype C infection.
Table 1. CAPRISA 002 participants included in this study.
PTID Clinical progression Viral load (1 year p.i.) CD4 count (1 year p.i.) Genetic diversity Timing of nAbs
(RNA copies/ml) (cells/ml) (1 year p.i.) (weeks p.i.)
CAP45 slow* 556 1,030 0.006 9
CAP88 intermediate 38,700 499 0.018 15
CAP177 intermediate 42,100 381 0.031 19
CAP210 rapid** 376,000 344 0.008 46
*Slow progressors have a consistent viral load ,2,000 RNA copies/ml.
**Rapid progressors have CD4 count ,350 cells/ml over the 1st year of infection.
Refer to Figure S1 for longitudinal viral load and CD4 count data.
doi:10.1371/journal.ppat.1000598.t001
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months post-infection (p.i.). Selected amplicons chosen to
represent each major clade in the phylogenetic tree were cloned
and tested against autologous plasma spanning the first 2 years of
infection. The neutralization curve when measured using the
earliest available clone, 88.1m.c17, had a biphasic shape, with one
peak at approximately 26 weeks p.i. and a second peak at 81 weeks
p.i. (Figure 1A). The neutralization curves for the 6 and 12 month
clones were shifted incrementally to the right (Figure 1A)
indicating neutralization escape. Escaped variants, however,
remained sensitive to later neutralizing antibody responses as
evidenced by the high titers using later plasma samples.
Furthermore, the varied curves shown by the multiple 12 month
clones (Figure 1A) suggested different pathways to escape.
Temporal variations in neutralization titers correspond to
waves of antibody specificities
We have previously probed the specificities of antibodies in
CAP88 using heterologous chimeras, where regions of interest in
CAP88 were transferred into an unrelated envelope, CAP63 [21].
Using this approach, serum from CAP88 was shown to contain at
least 2 antibody specificities within the first year of infection
targeting the C3 and the V1V2 regions. Here, longitudinal
analysis using the heterologous chimeras over the first 2 years of
infection suggested that each of the 2 peaks in the overall nAb
response comprised a single specificity (Figure 1B). The neutral-
ization curve using the heterologous chimeric envelope 63/88/63-
C3 (where the C3 region from CAP88 at 1 month p.i. was
transferred into the unrelated envelope, CAP63) mapped exactly
to the first peak of the overall nAb response, while the
neutralization curve of 63/88/63-V1V2 mapped to the second
peak. These data suggested that the autologous response in CAP88
consisted of an initial response to the C3 region, peaking at 26
weeks p.i. with a titer of ,1:4,000, and then waning so that by 54
weeks p.i. the titer had dropped to approximately 1:700. The
second specificity targeting the V1V2 region developed from a
titer of 1:60 at 26 weeks p.i. to peak at 81 weeks p.i. with a titer
exceeding 1:5,500, thereafter it too waned to a titer of ,1:2,000 by
108 weeks p.i. (Figure 1B).
We were interested in the relationship between these 2 defined
specificities and the neutralization escape occurring in CAP88.
Comparison of the neutralization curves of representative clones
from 1 month, 6 months and 12 months p.i. with the
neutralization data obtained using the heterologous chimeras
showed that the 1 month clone (in yellow) was sensitive to both the
anti-C3 and anti-V1V2 antibodies (Figure 1B). In contrast the 6
month clone matched the second peak indicating that this clone
had escaped the initial anti-C3 response but remained sensitive to
the anti-V1V2 antibodies. The 12 month clones had shifted still
further and had therefore escaped both the anti-C3 and anti-
Figure 1. Neutralization escape in CAP88. A) Development of a biphasic autologous neutralizing response against a 1 month clone, 88.1m.c17
(yellow line) with ID50 titers shown on the y-axis on a logarithmic scale, and weeks post-infection of plasma on the x-axis. Neutralization escape of 6
month (red lines) and 12 month (blue lines) envelope clones was evident by rightward shifts in neutralization curves. B) Neutralization of
heterologous chimeras 63-88-63-C3 (green line) and 63-88-63-V1V2 (gray line) overlaid on neutralization profiles of 6 month (red) and 12 month
clones (blue) showed the evolution of distinct specificities. C) CAP88.6m.c10 N339I, K350E (purple line), showed an increase in neutralization
sensitivity, shifting left to match 88.1m.c17 (yellow line). D) 88.12m.c2-V1V2s (green line) and 88.12m.c2-V1V2s, N339I, K350E (green/blue line) showed
incremental increases in neutralization sensitivity to match the 6 month clone 88.6m.c10 (red line) and 1 month clone, 88.1m.c17 (yellow line)
respectively.
doi:10.1371/journal.ppat.1000598.g001
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unidentified response.
Limited amino acid changes mediate neutralization
escape
Analysis of the C3 region of the 6 month amplicons showed that
each contained 2 potential escape mutations in the a2-helix; I339N
plus E343K or I339N plus E350K (Figure 2). Back mutation of the
I339N and E350K changes in a representative clone, CAP88.6m.c10,
to create the mutant envelope CAP88.6m.c10 N339I,K350E resulted
in the resistant 6 month clone acquiring complete neutralization
sensitivity, matching the 1 month clone (Figure 1C). The I339N
mutation in all 6 month amplicons created a potential N-linked
glycolsyation site [40,41,42] suggesting the possibility of glycan
shielding as a mechanism of escape. However, both the E343K and
E350K mutations resulted in charge switches from negatively charged
glutamic acid residues to positively charged lysine residues. The
charge alteration in each clone (at either position 343 or 350) may be
in response to conformational changes resulting from glycosylation at
the 339 residue. However mutagenesis studies in 88.6m.c10 showed
that the charge change at position 350, independently of the N339
PNG site (88.6m.c10 N339I) also conferred some sensitivity (titer of
548, Table 2), though much less profoundly than the sensitivity
conferred by both mutations (titer of 2,221, Table 2). This suggested
that charge changes in the absence of glycans may also contribute to
neutralization escape. The continuing pressure on the C3 region
remained evident at 12 months p.i. where despite the waning anti-C3
levels, there was maintenance of the I339N glycosylation site, in some
cases still with either E343K or E350K, plus an additional deletion in
most clones at N355 (Figure 2), the significance of which is not known.
Overall, by altering two amino acids in the C3 region the virus in
CAP88 escaped the anti-C3 antibodies that arose within the first 6
months of infection.
A similar approach was used to investigate neutralization escape
in the 12 month clones which were resistant to both specificities.
Since the number of mutations in V1V2 precluded testing all
changes by site-directed mutagenesis we used the whole V1V2
region to generate chimeras. Sequential autologous chimeras were
constructed using a 12 month clone, CAP88.12m.c2, firstly
introducing the V1V2 region from the sensitive early virus to
create 88.12m.c2-V1V2s then back-mutating the C3 region to
make 88.12m.c2-V1V2s,N339I,K350E. Use of these chimeras in
neutralization assays showed that 88.12m.c2-V1V2s became
sensitive to the second peak comprising anti-V1V2 antibodies,
but remained resistant to anti-C3 antibodies (Figure 1D), with the
neutralization curve of 88.12m.c2-V1V2s matching the 6 month
clone. The double chimera, 88.12m.c2-V1V2s,N339I,K350E
shifted still further, becoming as sensitive as the earliest virus to
both anti-C3 and anti-V1V2 antibodies (Figure 1D), suggesting
that in this 12 month clone, escape was mediated by changes in
V1V2 in addition to the maintenance of escape mutations in C3.
These included a 2 amino acid deletion in V1 as well as 3
substitutions in V2. Examination of all SGA amplicons at 12
months p.i. showed the addition of a PNG in V2 in 8 of 13
amplicons, suggesting a role for glycan shielding. The remaining 5
clones all contained a 2 amino acid deletion in the same region of
V2 which could perhaps re-orientate the loop resulting in ablation
of the epitope (Figure 2). Therefore, the mechanism of escape from
Figure 2. Amino acid alignment of the V1V2 (green) and C3 (blue) regions of single genome amplicons of CAP88. Amplicons were
derived from 1 month p.i. (yellow bar), 6 months p.i. (red bar) and 12 month p.i. (blue bars). Amplicons highlighted in bold text were cloned for
neutralization assays. Potential N-linked glycosylation sites are highlighted in gray, dashes indicate deletions.
doi:10.1371/journal.ppat.1000598.g002
Table 2. Role of individual escape mutations within CAP88
C3 mediating neutralization escape at 6 months p.i.
Clone ID Amino Acid Residues PNG Titer at 26 weeks pi.
339 350
88.1m.c17 I E no 2,989
88.6m.c10 N K yes 45
88.6m.c10 N339I I K no 548
88.6m.c10 N339I, K350E I E no 2,221
doi:10.1371/journal.ppat.1000598.t002
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individual, utilizing either deletions or glycan shielding.
Limited nAb specificities drive sequential escape
mutations
The concept of evolving nAb specificities which drive sequential
escape mutations was supported by data from a second individual,
CAP177. Envelope SGA amplicons were derived from CAP177 at
2 weeks (preseroconversion), 6 months and 12 months p.i. Use of
the transmitted envelope, inferred from the consensus sequence at
preseroconversion, 177.2wk.cA3, showed the development of
autologous nAbs by 19 weeks p.i., peaking at 1:5,500 at about
50 weeks p.i. (Figure 3A). Like CAP88, clones obtained at 6
months and 12 months p.i. all exhibited neutralization escape
(Figure 3A). Due to the relatively high levels of variability across
the envelope we again made use of autologous chimeric viruses,
where we exchanged either V1V2, C2, C3, V4 or C3-V4 (regions
exhibiting changes in all 12 month clones) between the sensitive
preseroconversion envelope and a representative clone from 6
months and 12 months p.i. When the C3 region from the
Figure 3. Neutralization escape in CAP177. A) Development of an autologous neutralizing response against a preseroconversion clone,
177.2wk.cA3 (yellow line) with ID50 titers on the y-axis, weeks post-infection of plasma on the x-axis. Neutralization escape occurred in clones from 6
months (red lines) and 12 months (blue lines) p.i. B) 177.6m.c8B-C3s (purple line), a 6 month clone containing the preseroconversion C3 sequence,
showed an increase in neutralization sensitivity, shifting to the left towards the preseroconversion clone, 177.2wk.cA3. C) 177.12m.c1-V1V2s, the 12
month clone containing the V1V2 of the preseroconversion envelope gained neutralization sensitivity, evident in a shift to the left so that the
chimeric envelope matches the earlier clone, 177.6m.c8B.
doi:10.1371/journal.ppat.1000598.g003
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177.6m.c8B to form 177.6m.c8B-C3s, neutralization sensitivity
increased markedly, with titers higher than those seen with
177.2wk.cA3, although the shapes of the curve were remarkably
similar (Figure 3B). The increase in sensitivity of the 177.6m.c8B-
C3zs envelope suggested that, as with CAP88, escape initially
occurred via changes in the C3 region. Four changes were noted
in the C3 of 177.6m.c8B (Figure S2), one of which resulted in a
shift in the position of a PNG, though the overall number of PNGs
in the region remained unchanged. All four changes were charge
changes from neutral or negatively charged residues to positively
charged residues. This was similar to CAP88 although the fact that
mutated residues differed between clones at 6 months p.i. in both
CAP88 and CAP177 suggested multiple mechanisms of escape
within C3 even in a single individual.
When we examined neutralization escape at 12 months p.i.,
transfer of the V1V2 region from the preseroconversion envelope
into 177.12m.c1 to form 177.12m.c1-V1V2s resulted in a shift
leftwards of the neutralization curve, with the chimeric envelope
becoming as sensitive to neutralization as the 6 month clone
(Figure 3C). All of the 12 month clones contained at minimum a 3
amino acid insertion in the V1 loop, resulting in the addition of
either one or two novel PNGs (Figure S2). It is likely that the
extended loop length in addition to the novel PNGs mediated
escape through shielding of neutralization epitopes. These data
support the notion that waves of nAb specificities drive sequential
escape mutations over the first year of infection.
The V1V2 region may serve as a nAb target, and also
directly mediate neutralization escape
A role for autologous nAbs targeting V1V2, with escape
mutations occurring directly in V1V2 was also shown in CAP210.
The autologous neutralizing response in CAP210, a rapid
progressor, was of low magnitude and only became consistently
detectable at 46 weeks p.i. when measured against the transmitted
envelope (yellow) (Figure 4A). Neutralization escape in CAP210
occurred late, with the 1 month and 6 month clones showing
identical sensitivity to the earlier envelope despite occasional
sequence changes (Figure S3). This was unsurprising considering
the absence of measurable nAbs at these time points. In contrast
the 12 month clones, from a time-point very shortly after the
development of measurable autologous nAbs did exhibit neutral-
ization escape with a shift to the right in the neutralization curves.
As with CAP88, we constructed a heterologous chimera for the
V1V2 region (where the majority of amino acid changes were
located in 12 month clones) to assess whether anti-V1V2
antibodies mediated autologous neutralization. We observed
transfer of neutralization sensitivity using the heterologous 84/
210/84-V1V2 chimera (where the V1V2 region from
CAP210.2wk.cTA5 was transferred into the unrelated envelope
CAP84) suggesting that anti-V1V2 antibodies were present in
CAP210 sera from 54 weeks p.i., coinciding with the timing of
detectable autologous nAbs (Figure 4B).
In order to assess whether changes in V1V2 also mediated
escape in CAP210, as we had shown in CAP88 and CAP177, we
created an autologous chimera, transferring the V1V2 region from
the early sensitive clone into a 12 month resistant clone,
210.12m.c12. The autologous V1V2 chimeric envelope,
210.12m.c12-V1V2s showed a shift left in the neutralization
curve, becoming as sensitive as the early preseroconversion
envelope (Figure 4C). While all CAP210 12 month SGA sequences
contained an A153V mutation at the beginning of V2, the
presence of this change in the sensitive 6 month clone 210.6m.cC9
and other amplicons from 6 months p.i., suggested that this
mutation was not involved in neutralization escape (Figure S3). In
resistant clone 210.12m.c12 there were no changes in PNG sites,
although a 2 amino acid deletion at position 180 between 2 PNGs
could perhaps alter the arrangement of the PNGs in this clone.
Alternatively, deletion may alter the conformation or directly
ablate the epitope independently of glycosylation. In contrast,
clones 210.12m.c47 and 210.12m.c66 (which had superimposable
neutralization curves and were slightly more sensitive than
210.12m.c12) both had the addition of a single PNG in V1 at
position 132, as well as an E181K change between two PNGs.
Overall, these data suggested that the initial autologous nAb
response in CAP210 was comprised solely of anti-V1V2
antibodies, which drove neutralization escape via mutations within
V1V2, likely via shifting glycans.
Changes outside the antibody target may mediate
escape
In a fourth individual, CAP45, previous analyses suggested that
autologous nAbs targeted C3-V4 and V1V2 [21]. CAP45 who was
a slow progressor developed a robust autologous response by 9
weeks p.i. peaking at titers exceeding 1:6,000 at 43 weeks p.i. when
measured against the transmitted envelope (Figure 5A). Envelope
clones obtained at 4 months, 8 months and 12 months p.i. escaped
the early nAbs as shown by the increasing shift right in the
neutralization curves. Inspection of SGA sequences showed
potential escape mutations in V1V2, however despite data
suggesting the C3-V4 region was a target, there were no changes
in C3-V4 indicating that escape occurred by a more indirect
mechanism. The level of genetic diversity in CAP45 was very low,
and so it was possible to examine all changes using site-directed
mutagenesis. We back-mutated each of the 8 changes observed in
a 12 month clone, 45.12m.c7 to match the preseroconversion
motifs.
Mutations in the V1V2 region contributed marginally to
neutralization sensitivity in CAP45 (Figure 5B). The S147N
change in V1, which resulted in the shift by one amino acid of a
PNG (Figure 5B, green line and Figure S4), and the mutations
observed in V2 (K181R, G186E, neither of which impacted on
PNG formation) (Figure 5B, blue line) both increased neutraliza-
tion sensitivity with relatively low titers of ,1:500 and ,1:900
respectively. This did not conflict with data obtained using the
heterologous chimera which suggested only low level anti-V1V2
nAbs in CAP45 serum, becoming detectable at 35 weeks p.i. and
not exceeding a titer of 1:800 (data not shown). However neither of
these changes in V1V2 accounted for complete restoration of
neutralization sensitivity. The most significant escape mutations
observed in CAP45 were located in V5 (K460E, D462G), and
neither affected glycosylation. Simultaneous back-mutation of
these 2 residues to match the preseroconversion motif resulted in
almost complete restoration of sensitivity (Figure 5C, pink line). No
other mutations observed in resistant 12 month clones impacted
on neutralization sensitivity when back-mutated to preseroconver-
sion motifs (data not shown).
Making use of heterologous chimeras described previously [21],
we saw no evidence for anti-V5 antibodies in CAP45, suggesting
that V5 is unlikely to be a direct target of nAbs in CAP45. It seems
more likely that V5, and escape mutations therein, were
responsible for exposure of epitope(s) in other regions of the
envelope, perhaps in C3-V4 which is in relatively close proximity
to V5 (Gnanakaran, pers comm), and which we proposed to be a
nAb target in CAP45 [21]. Nevertheless, the existence of one
significant mechanism of escape in CAP45 at 12 months p.i.
suggests that, as with CAP210, a single neutralizing antibody was
solely responsible for driving escape in this individual.
Neutralization Escape in HIV-1 Subtype C
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Given that a single amino acid change (I339N) was associated
with escape from the anti-C3 antibody in CAP88, this allowed us
to measure the timing of the emergence of the escape mutation
relative to the appearance of the antibody. We made use of
quantitative allele-specific real-time PCR to investigate the
development of the I339N change in the C3 over time.
Figure 6A shows the decline in the wild-type (I339) residue from
100% to approximately 10% of the total circulating population,
with a concomitant increase in the proportion of the I339N
mutation by 26 weeks p.i. Interestingly, there was a 7 week gap
between detectable neutralizing antibodies and the appearance of
escape mutations. This suggested that relatively high levels of
autologous nAbs were needed to impact on the evolution of
genetic escape mutations.
Development of the anti-C3 response corresponded temporally
with an 86% decrease in viral load from 93,400 RNA copies/ml at
11 weeks p.i. to 12,800 copies/ml by 15 weeks p.i. (Figure 6B). At
this stage (15 weeks p.i.) 90% of circulating virus remained
genotypically wild-type. The viral load rebounded to reach a level
of 50,500 copies/ml at 22 week p.i., at which stage the escape
mutant dominated the viral population. Extrapolation of the real-
time PCR data to determine the wild-type and mutant viral load
suggested that the wild-type virus continued to decline reaching
Figure 4. Neutralization escape in CAP210. A) Development of a delayed autologous neutralizing response against a preseroconversion clone,
210.2wk.cTA5. Clones obtained at 1 month p.i. (orange line) and 6 months p.i. (red lines) showed no neutralization escape, in contrast to clones
obtained at 12 months p.i. (blue lines). B) Neutralization of the heterologous chimera 84-210-84-V1V2 (gray line) showed the development of anti-
V1V2 antibodies from 54 weeks p.i. C) 210.12m.c12-V1V2s, a resistant 12 month clone (green line) that contained the V1V2 region from the
preseroconversion envelope showed an increase in neutralization sensitivity to match the preseroconversion clone 210.2wk.cTA5 (yellow line).
doi:10.1371/journal.ppat.1000598.g004
Neutralization Escape in HIV-1 Subtype C
PLoS Pathogens | www.plospathogens.org 7 September 2009 | Volume 5 | Issue 9 | e1000598levels of approximately 1,900 copies/ml at 26 weeks p.i. This
suggested that the potent nAbs identified in vitro and through
analyses of genetic escape impacted at least in the short-term on
viral levels in vivo.
Discussion
This study aimed to identify the antibody specificities mediating
autologous neutralization in HIV-1 subtype C infection during the
first year of infection, and investigate the mechanisms of viral escape
from these antibodies. We showed that neutralization escape
occurred shortly after the appearance of nAbs, and was mediated
by relatively few amino acid changes, including substitutions, indels,
and glycan shifts, commonly in the V1V2 and C3 regions. A limited
number of specificities were responsible for driving genetic escape
and these antibodies appeared sequentially and waned as escape
mutations emerged. A schematic representation of the targets of
autologous nAbs as well as the regions or residues involved in
neutralization escape are shown in Figure 7.
The investigation of neutralization escape in conjunction with
data examining the specificity of the circulating nAbs is a strength
of this study. We examined neutralization escape in four
individuals, with varying disease status and viral genetic diversity.
In CAP45 and CAP210, where genetic diversity at 1 year p.i. was
low, use of chimeric and mutant envelopes indicated the
development of only a single nAb specificity resulting in
neutralization escape. The low levels of viremia in CAP45 who
was classified as a controller (Table 1), may have resulted in
minimal antigenic stimulation of B cells, perhaps accounting for
the development of only a single specificity. In contrast, in
Figure 5. Neutralization escape in CAP45. A) Development of an autologous neutralizing response against a preseroconversion clone, 45.2wk.c9
(yellow line) with ID50 titers on the y-axis, weeks post-infection on the x-axis. Neutralization escape occurred in clones from 6 months (red lines) and
12 months (blue lines) p.i. B) Site-directed mutants of the escaped 12 month clone 45.12m.c7 to restore N147S in V1 (green line) and R181K/E186G in
V2 (cyan line) to preseroconversion motifs resulted in slight acquisition of sensitivity compared to the resistant 12 month clone (blue line). C) Site-
directed mutation of 45.12m.c7 to restore E460K/G462D in V5 (pink line) to preseroconversion motifs resulted in complete restoration of sensitivity,
with the neutralization profile matching the preseroconversion clone, 45.2wk.c9 (yellow line).
doi:10.1371/journal.ppat.1000598.g005
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somewhat surprising that the high antigenic load did not result in
many more specificities and much earlier development of a nAb
response. It is possible that the high viral load in CAP210
impacted on B cell dysfunction, delaying the development of nAbs
(Table 1). In CAP88 and CAP177, both of whom exhibited higher
genetic diversity after 1 year of infection, two distinct nAb
specificities were involved in driving escape within the first year of
infection. It is not clear whether the increased diversity was
responsible for generating multiple antibody specificities, or
whether the reverse is true. However, it was interesting to note
that a very small proportion of these changes were directly
involved in neutralization escape. CAP88 had an envelope CTL
response targeting C2 (Clive Gray, pers comm) which resulted in
genotypic changes in this region. Thus, nAb and CTL pressure
directly accounted for 7 of the 14 mutations found in the CAP88
envelope, with the remaining 7 mutations playing no obvious role
in immune escape. Thus, attributing bulk variation in envelope
sequences largely to immune pressure may overstate the direct
effect of early nAbs on envelope variation. Of course, it is likely
that other mutations may indirectly affect neutralization sensitivity
via e.g. changes in fitness or entry efficiency which could increase
the overall neutralization resistance, but which should be
differentiated from specific changes mediating neutralization
escape from single antibody specificities.
Changes within the V1V2region wereimplicated inneutralization
escape in all 4 individuals (Figure 7) although in CAP45 this was
minor. This observation is perhaps not particularly surprising, as the
role of V1V2 in shielding neutralization determinants is well-
recognized [19,20,22,23,24,25,26]. Furthermore, we and others have
proposed that the V1V2 may serve as a neutralization target in some
cases [1,18,21]. Here we show clearly in 2 cases (CAP88 and
CAP210), using heterologous chimeric viruses, evidence for nAbs
which directly target the V1V2 region with neutralization escape
occurring via changes within this region. Such changes were variable
even within a single individual and involved multiple mechanisms. In
CAP88, the unique V1V2 sequences in each of the 13 amplicons
obtained at 12 months p.i. suggested that escape from the anti-V1V2
response occurred via either glycan shifts, indels or substitutions
(Figure 2). Similarly, in CAP210, virtually every amplicon was unique
within the V1V2 (Figure S3). Although for both CAP88 and
CAP210, phenotypic testing was only performed on selected clones,
the presence in plasma of these multiple variants suggests the
likelihood that such sequence changes also confer escape. While
c h a n g e sw i t h i nV 1 V 2a l s oc o n f e r r e dn e u t r a l i z a t i o ne s c a p ei n
CAP177 we could not determine whether V1V2 was a direct
antibody target in this case (Figure 7). Collectively, these observations
suggest that V1V2 utilizes many pathways to escape, even when the
selection pressure is induced by a single antibody specificity, almost
certainly reflecting the extreme plasticity of the V1V2 region.
Figure 6. Defining the rate of neutralization escape and impact of nAbs on viral load. A) Rate of development of I339N escape mutation in
CAP88. Relative proportion of wildtype I339 (blue line, right axis), escape mutant N339 (red line, right axis) and percentage neutralization at 1:45
plasma dilution (green line, left axis) versus weeks post-infection. Relative proportions of wild-type and mutant codons were quantified using an
allele-specific PCR for the 339 locus. B) Percentage neutralization at 1:45 plasma dilution (green line, left axis), overall viral load (black line, right axis),
wild type viral load (dotted blue line, right axis) and mutant viral load (dotted red line, right axis) versus weeks post-infection. Gray shading indicates a
decrease in VL associated with the development of nAbs, and brown shading an increase with VL associated with neutralization escape.
doi:10.1371/journal.ppat.1000598.g006
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of autologous nAbs in subtype C [21]. In general, the a2-helices of
subtype C viruses have more defined polar and non-polar faces
than those in subtype B which are more hydrophobic [37]. This
amphipathicity, characteristic of surface helices, suggests that the
a2-helix in subtype C may be more exposed. Indeed, it has been
proposed that nAbs directly target the a2-helix in subtype C
viruses, a possibility supported by our recent data [21].
Furthermore, the C3 region of the HIV-1 subtype C envelope,
including mutational patterns within the a2-helix, has been
implicated in neutralization resistance [39]. Here we show that
in CAP88 and CAP177, neutralization escape from anti-C3 nAbs
was mediated by changes in the a2-helix of the C3 region
(Figure 7). In CAP88 we were able to confirm that the C3 region
was a direct target of nAbs. However, in both cases, neutralization
escape was associated with charge changes within the a2-helix, all
of which were located in the solvent-exposed portions of the helix
maintaining the amphipathic structure. Neutralization escape in
these 2 individuals was associated with an overall increase in
positively charged residues within the a2-helix. While switching
between oppositely charged residues within the a2-helix has been
proposed to be mediate immune escape in subtype C viruses
[37,39], the precise mechanism whereby charge changes abrogate
neutralization is unclear. Charge changes may simply disrupt the
Figure 7. Summary of the location of the targets of autologous nAbs and resulting escape mutations. A) Location of regions targeted
by nAbs on a liganded structure of gp120 [52] (with early targets shown in orange, and later targets shown in purple) and the locations of escape
mutations (early mutations in cyan and later mutations in dark blue). B) a linear representation of the regions targeted by autologous nAbs and of
resulting mutations showing the sequential development of specificities.
doi:10.1371/journal.ppat.1000598.g007
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is a direct target, as we have shown in CAP88. Alternatively, since
there are strong interactions between the N-terminus of the a2-
helix and the C-terminus of the V4 region [37], with the
conservation of a charge anti-correlation between the two regions,
charge changes within the a2-helix may affect the conformation of
the V4 loop with respect to the a2-helix, affecting the exposure of
nAb targets in the C3 region or elsewhere.
The sequential development of nAb specificities, sometimes
requiring months of infection was intriguing considering that the
targets of these antibodies may have been present in the infecting
virus. This is most clearly exhibited in CAP88 where an initial
anti-C3 response developed, waned and was subsequently
replaced by an anti-V1V2 response. The V1V2 epitope that was
the target of this secondary response was present in the earliest
virus, cloned at 1 month p.i. Despite the ongoing presentation of
this epitope, an anti-V1V2 response was only detectable at 26
weeks p.i., 11 weeks after the detection of the initial anti-C3
response, suggesting the possibility of an immunological hierarchy.
Delayed development of selected responses would be in line with
the hierarchical binding antibody responses which develop in the
very early stages of infection [43], prior to the development of
nAbs. It is also possible that other changes which develop across
the entire envelope during the first 6 months of infection affected
the conformation and exposure of the secondary nAb target,
V1V2, facilitating presentation of this region to the immune
system only at a later time-point.
Of interest was the observation that after escape occurred,
although specific responses waned, they continued to be
maintained at somewhat lower levels. This was difficult to discern
when looking at overall neutralization levels as novel responses
replaced waning responses. However, the use of heterologous
viruses in CAP88 clearly showed that the anti-C3 response was
maintained, albeit at lower levels (declining from a peak of
.1:3,000 to stabilize at approximately 1:700 during the second
year of infection). How this response was maintained is not clear as
by 6 months p.i., 8/8 envelope clones contained escape mutations
which presumably no longer stimulated the B cells responsible for
producing anti-C3 antibodies. It is possible that even after escape
has occurred, low levels of sensitive variants remain in the lymph
nodes and stimulate maintenance of low levels of antibodies. The
persistence of such sensitive variants in the face of potent nAbs as
reported by Mahalanbis et al [16], may result from continuous
reversion of less fit escape variants, or persistent release of pre-
escape variants from cell reservoirs. Alternatively, long-lived
memory or plasma B cells may be responsible for the maintenance
of specific responses in the absence of antigenic stimulation.
The identification of a single amino acid change associated with
initial neutralization escape in CAP88 afforded us the opportunity
to investigate the kinetics of the development of neutralization
escape with respect to the timing of the autologous neutralization
response. The relationship between percentage neutralization at a
1:45 plasma dilution and development of the initial escape
mutation, showed a lag of 7 weeks in the development of genetic
escape. This suggested a threshold requirement, whereby relatively
high titers of nAbs were needed before sufficient pressure was
exerted on the overall population, forcing escape to occur.
Maturation of the antibody response, in terms of affinity and
avidity may also play a role in the duration of time required for
escape to occur. The decrease in the viral load which occurred as
the autologous neutralizing antibody response developed was
intriguing, suggesting the possibility that autologous nAbs may in
the short term impact on viral load, with this effect abrogated by
the development of neutralization escape mutations.
The observation of the sequential development of anti-C3
antibodies followed by anti-V1V2 antibodies suggests that both of
these regions are exposed and immunogenic on the HIV-1 subtype
C envelope, possibly due to unique structural features of this viral
subtype. Further studies are needed to determine if this is a
common pattern, and whether emergence of these autologous
antibodies is associated with decreases in HIV-1 viral load as seen
in one individual who developed an anti-C3 specific nAb.
However, as shown here, escape variants emerged as a result of
a few genetic changes, not unlike the scenario with anti-retroviral
monotherapy. The ease with which escape occurred, and the
multiple pathways used to escape autologous responses further
supports the notion that these responses, while driving consider-
able variation in the envelope region, have no long-term role in
containing viral replication. Nonetheless, neutralization escape is
reflective of active and ongoing replication in the face of an
evolving and initially very low titer response, considerably different
to a possible future vaccine scenario with pre-existing antibodies.
Overall, these data provide insight into how a focused antibody
response targeting limited regions of envelope in early subtype C
infection drives sequential waves of neutralization escape.
Materials and Methods
Ethics statement
The CAPRISA Acute Infection study was reviewed and approved
b yt h er e s e a r c he t h i c sc o m m i t t e e so ft h eU n i v e r s i t yo fK w a Z u l u -
Natal (E013/04), the University of Cape Town (025/2004), and the
University of the Witwatersrand (MM040202). All participants
provided written informed consent for study participation.
Participants
Participants were from the CAPRISA 002 Acute Infection study,
a cohort of 245 high risk HIV negative women which was
established in 2004 in Durban, South Africa for follow-up and
subsequent identification of HIV seroconversion [44]. The 4
individuals studied here included one controller (CAP45), one
rapid progressor (CAP210) and 2 individuals classified as interme-
diate progressors (CAP88 and CAP177). Clinical profiles indicating
viral loads and CD4 counts of eachare shown in Figure S1. CAP45,
CAP177 and CAP210 were all infected by single transmitted
variants [45], with the transmitted envelope sequence inferred from
the consensus sequence at the earliest available timepoint.
Cell lines
The JC53bl-13 cell line, engineered by J. Kappes and X. Wu,
was obtained from the NIH AIDS Research and Reference
Reagent Program. 293T cells were obtained from Dr George
Shaw (University of Alabama, Birmingham, AL). Both cell lines
were cultured in D-MEM (Gibco BRL Life Technologies)
containing 10% heat-inactivated fetal bovine serum (FBS) and
50 ug/ml gentamicin (Sigma). Cell monolayers were disrupted at
confluency by treatment with 0.25% trypsin in 1 mM EDTA.
Single genome amplification and sequencing
HIV-1 RNA was purified from plasma using the Qiagen Viral
RNA kit, and reverse transcribed to cDNA using Superscript III
Reverse Transcriptase (Invitrogen, CA). The env genes were
amplified from single cDNA copies [46] and amplicons were
directly sequenced using the ABI PRISM Big Dye Terminator
Cycle Sequencing Ready Reaction kit (Applied Biosystems, Foster
City, CA) and resolved on an ABI 3100 automated genetic
analyzer. The full-length env sequences were assembled and edited
using Sequencher v.4.0 software (Genecodes, Ann Arbor, MI).
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determined using N-glycosite (http:/www.hiv.lanl.gov/content/
hiv-db/GLYCOSITE/glycosite.html). Multiple sequence align-
ments were performed using Clustal X (ver. 1.83) and edited with
BioEdit (ver. 5.0.9). Pairwise DNA distances were computed using
Mega 4 [47].
Cloning gp160 and production of pseudoviruses
Selected amplicons were cloned into the expression vector
pCDNA 3.1 (directional) (Invitrogen) by re-amplification of SGA
first-round products using Phusion enzyme (Finn Enzymes) with
the EnvM primer [48] and directional primer, EnvAdir [21]. Env-
pseudotyped viruses were obtained by co-transfecting the Env
plasmid with pSG3DEnv [4] using Fugene transfection reagent
(Roche) as previously described [1].
Generation of chimeras and mutant envelopes
Chimeric Env were created using an overlapping PCR strategy
with the inserts and flanking regions amplified in separate
reactions. After linkage, the 3 Kb chimeric PCR fragments,
generated using EnvAdir and EnvM primers [48], were cloned
into the pCDNA 3.1 (directional) (Invitrogen) and screened for
function as previously described [49]. Chimerism was confirmed
by sequence analysis. Site-directed mutagenesis was performed
using the Stratagene QuickChange II kit (Stratagene)
Neutralization assays
Neutralization was measured as described previously [1] by a
reduction in luciferase gene expression after single round infection
of JC53bl-13 cells with Env-pseudotyped viruses [50]. Titers were
calculated as the reciprocal plasma dilution (ID50) causing 50%
reduction of relative light units (RLU).
Quantitative real-time PCR
Real-time PCR was performed on RNA extracted from
sequential plasma samples of CAP88 using the QIAamp Viral
RNA Mini Kit (Qiagen). HIV-1 RNA was reverse transcribed to
cDNA using the Superscript III Reverse Transcriptase System
(Invitrogen) using the primer OFM19 as described [51]. cDNA
was used in real-time PCR, making use of the following primers
designed to detect the 339I and 339N residues: 88AS-PCR-T-for
(CAT TAC TAA AGA CAG ATG Gtt) for detection of the 339I,
88AS-PCR-A-for (CAT TAC TAA AGA CAG ATG Gta) for the
detection of 339N. Control primers were 88AS-PCR-control
(GAG ATA TAA GAC AAG CAC ATT G) and 88AS-PCR-A/
T-rev (CTA TGT GTT GTA ACT TCT AGG). The reaction
was performed using ABI PowerSYBR Green PCR master mix, in
the ABI 7500 Real Time PCR System. Primer concentrations
were 300 nM, final volume 25 ul. Cycling was performed as
follows: 95uC for 10 minutes followed by 45 cycles of 95uC for
15 seconds, 60uC for 15 seconds, and 72u for 1 minute, for a total
of 45 cycles. Relative quantification of mutation frequency was
determined by calculating the number of copies of wild type and
mutant populations relative to an internal control.
Supporting Information
Figure S1 Clinical profiles of CAP45, CAP88, CAP177 and
CAP210. Viral load (copies/ml) in red and CD4 count (cells/ml) in
blue. Clinical status for each individual is indicated in parentheses.
Arrows indicate time points at which SGA amplicons were derived.
Found at: doi:10.1371/journal.ppat.1000598.s001 (0.19 MB TIF)
Figure S2 Clinical profiles of CAP45, CAP88, CAP177 and
CAP210. Viral load (copies/ml) in red and CD4 count (cells/ml) in
blue. Clinical status for each individual is indicated in parentheses.
Arrows indicate time points at which SGA amplicons were derived.
Found at: doi:10.1371/journal.ppat.1000598.s002 (0.47 MB TIF)
Figure S3 Amino acid alignment of the V1V2 regions of single
genome amplicons of CAP210. Amplicons were derived from 1
month p.i. (yellow bar), 1 month p.i. (orange bar), 6 months p.i. (red
bar)and12monthp.i.(bluebar).Ampliconshighlighted inbold text
were cloned for neutralization assays. Potential N-linked glycosyl-
ation sites are highlighted in gray, dashes indicate deletions.
Found at: doi:10.1371/journal.ppat.1000598.s003 (0.24 MB TIF)
Figure S4 Amino acid alignment of the mutation observed in
V1 (green), V2 (cyan) and V5 (pink) regions of single genome
amplicons of CAP45. Amplicons were derived from 2 weeks p.i.
(yellow bar), 1 month (orange), 6 months (red bar) and 12 months
p.i. (blue bar). Amplicons highlighted in bold text were cloned for
neutralization assays. Potential N-linked glycosylation sites are
highlighted in gray, dashes indicate deletions.
Found at: doi:10.1371/journal.ppat.1000598.s004 (0.23 MB TIF)
Acknowledgments
We thank the participants in the CAPRISA AI cohort, and the clinical and
laboratory staff at CAPRISA for providing specimens. We are grateful to
Mary Phoswa and Sarah Cohen for sample and data management and Dr
Gillian Hunt for technical assistance. We thank Dr. Gnana Gnanakaran
and Dr. Cynthia Derdeyn for useful discussions and Dr. James Binley for
insightful comments on the manuscript.
Author Contributions
Conceived and designed the experiments: PLM ESG LM. Performed the
experiments: PLM NR BEL EC. Analyzed the data: PLM NR BEL ESG
EC LM. Contributed reagents/materials/analysis tools: MRA GB KM
S S A KC W .W r o t et h ep a p e r :P L ME S GC WL M .C o n c e i v e d ,
implemented and led the CAPRISA 002 Acute Infection study: KM
SSAK CW.
References
1. Gray ES, Moore PL, Choge IA, Decker JM, Bibollet-Ruche F, et al. (2007)
Neutralizing antibody responses in acute human immunodeficiency virus type 1
subtype C infection. J Virol 81: 6187–6196.
2. Li B, Decker JM, Johnson RW, Bibollet-Ruche F, Wei X, et al. (2006) Evidence
for potent autologous neutralizing antibody titers and compact envelopes in
early infection with subtype C human immunodeficiency virus type 1. J Virol 80:
5211–5218.
3. Richman DD, Wrin T, Little SJ, Petropoulos CJ (2003) Rapid evolution of the
neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A
100: 4144–4149.
4. Wei X, Decker JM, Wang S, Hui H, Kappes JC, et al. (2003) Antibody
neutralization and escape by HIV-1. Nature 422: 307–312.
5. Delwart EL, Pan H, Sheppard HW, Wolpert D, Neumann AU, et al. (1997)
Slower evolution of human immunodeficiency virus type 1 quasispecies during
progression to AIDS. J Virol 71: 7498–7508.
6. Albert J, Abrahamsson B, Nagy K, Aurelius E, Gaines H, et al. (1990) Rapid
development of isolate-specific neutralizing antibodies after primary HIV-1
infection and consequent emergence of virus variants which resist neutralization
by autologous sera. AIDS 4: 107–112.
7. Arendrup M, Nielsen C, Hansen JE, Pedersen C, Mathiesen L, et al. (1992)
Autologous HIV-1 neutralizing antibodies: emergence of neutralization-resistant
escape virus and subsequent development of escape virus neutralizing antibodies.
J Acquir Immune Defic Syndr 5: 303–307.
8. Bradney AP, Scheer S, Crawford JM, Buchbinder SP, Montefiori DC (1999)
Neutralization escape in human immunodeficiency virus type 1-infected long-
term nonprogressors. J Infect Dis 179: 1264–1267.
9. Montefiori DC, Altfeld M, Lee PK, Bilska M, Zhou J, et al. (2003) Viremia
control despite escape from a rapid and potent autologous neutralizing antibody
response after therapy cessation in an HIV-1-infected individual. J Immunol
170: 3906–3914.
Neutralization Escape in HIV-1 Subtype C
PLoS Pathogens | www.plospathogens.org 12 September 2009 | Volume 5 | Issue 9 | e100059810. Tremblay M, Wainberg MA (1990) Neutralization of multiple HIV-1 isolates
from a single subject by autologous sequential sera. J Infect Dis 162: 735–737.
11. Geffin R, Hutto C, Andrew C, Scott GB (2003) A longitudinal assessment of
autologous neutralizing antibodies in children perinatally infected with human
immunodeficiency virus type 1. Virology 310: 207–215.
12. Bunnik EM, Pisas L, van Nuenen AC, Schuitemaker H (2008) Autologous
neutralizing humoral immunity and evolution of the viral envelope in the course
of subtype B human immunodeficiency virus type 1 infection. J Virol 82:
7932–7941.
13. Burns DP, Collignon C, Desrosiers RC (1993) Simian immunodeficiency virus
mutants resistant to serum neutralization arise during persistent infection of
rhesus monkeys. J Virol 67: 4104–4113.
14. Burns DP, Desrosiers RC (1991) Selection of genetic variants of simian
immunodeficiency virus in persistently infected rhesus monkeys. J Virol 65:
1843–1854.
15. Kinsey NE, Anderson MG, Unangst TJ, Joag SV, Narayan O, et al. (1996)
Antigenic variation of SIV: mutations in V4 alter the neutralization profile.
Virology 221: 14–21.
16. Mahalanabis M, Jayaraman P, Miura T, Pereyra F, Chester EM, et al. (2009)
Continuous viral escape and selection by autologous neutralizing antibodies in
drug-naive human immunodeficiency virus controllers. J Virol 83: 662–672.
17. Frost SD, Wrin T, Smith DM, Kosakovsky Pond SL, Liu Y, et al. (2005)
Neutralizing antibody responses drive the evolution of human immunodeficiency
virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci U S A
102: 18514–18519.
18. Rong R, Bibollet-Ruche F, Mulenga J, Allen S, Blackwell JL, et al. (2007) Role
of V1V2 and other human immunodeficiency virus type 1 envelope domains in
resistance to autologous neutralization during clade C infection. J Virol 81:
1350–1359.
19. Sagar M, Wu X, Lee S, Overbaugh J (2006) Human immunodeficiency virus
type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over
the course of infection, and these modifications affect antibody neutralization
sensitivity. J Virol 80: 9586–9598.
20. Chackerian B, Rudensey LM, Overbaugh J (1997) Specific N-linked and O-
linked glycosylation modifications in the envelope V1 domain of simian
immunodeficiency virus variants that evolve in the host alter recognition by
neutralizing antibodies. J Virol 71: 7719–7727.
21. Moore PL, Gray ES, Choge IA, Ranchobe N, Mlisana K, et al. (2008) The C3-
V4 region is a major target of autologous neutralizing antibodies in human
immunodeficiency virus type 1 subtype C infection. J Virol 82: 1860–1869.
22. Krachmarov C, Pinter A, Honnen WJ, Gorny MK, Nyambi PN, et al. (2005)
Antibodies that are cross-reactive for human immunodeficiency virus type 1
clade a and clade B v3 domains are common in patient sera from Cameroon,
but their neutralization activity is usually restricted by epitope masking. J Virol
79: 780–790.
23. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, et al. (1998) Structure
of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a
neutralizing human antibody. Nature 393: 648–659.
24. Pinter A, Honnen WJ, He Y, Gorny MK, Zolla-Pazner S, et al. (2004) The V1/
V2 domain of gp120 is a global regulator of the sensitivity of primary human
immunodeficiency virus type 1 isolates to neutralization by antibodies commonly
induced upon infection. J Virol 78: 5205–5215.
25. Krachmarov CP, Honnen WJ, Kayman SC, Gorny MK, Zolla-Pazner S, et al.
(2006) Factors determining the breadth and potency of neutralization by V3-
specific human monoclonal antibodies derived from subjects infected with clade
A or clade B strains of human immunodeficiency virus type 1. J Virol 80:
7127–7135.
26. Wyatt R, Moore J, Accola M, Desjardin E, Robinson J, et al. (1995) Involvement
of the V1/V2 variable loop structure in the exposure of human immunodefi-
ciency virus type 1 gp120 epitopes induced by receptor binding. J Virol 69:
5723–5733.
27. Fung MS, Sun CR, Gordon WL, Liou RS, Chang TW, et al. (1992)
Identification and characterization of a neutralization site within the second
variable region of human immunodeficiency virus type 1 gp120. J Virol 66:
848–856.
28. Gorny MK, Moore JP, Conley AJ, Karwowska S, Sodroski J, et al. (1994)
Human anti-V2 monoclonal antibody that neutralizes primary but not
laboratory isolates of human immunodeficiency virus type 1. J Virol 68:
8312–8320.
29. Kayman SC, Wu Z, Revesz K, Chen H, Kopelman R, et al. (1994) Presentation
of native epitopes in the V1/V2 and V3 regions of human immunodeficiency
virus type 1 gp120 by fusion glycoproteins containing isolated gp120 domains.
J Virol 68: 400–410.
30. Li Y, Svehla K, Mathy NL, Voss G, Mascola JR, et al. (2006) Characterization
of antibody responses elicited by human immunodeficiency virus type 1 primary
isolate trimeric and monomeric envelope glycoproteins in selected adjuvants.
J Virol 80: 1414–1426.
31. McKeating JA, Shotton C, Cordell J, Graham S, Balfe P, et al. (1993)
Characterization of neutralizing monoclonal antibodies to linear and confor-
mation-dependent epitopes within the first and second variable domains of
human immunodeficiency virus type 1 gp120. J Virol 67: 4932–4944.
32. Pinter A, Honnen WJ, D’Agostino P, Gorny MK, Zolla-Pazner S, et al. (2005)
The C108g epitope in the V2 domain of gp120 functions as a potent
neutralization target when introduced into envelope proteins derived from
human immunodeficiency virus type 1 primary isolates. J Virol 79: 6909–6917.
33. Wu L, Yang ZY, Xu L, Welcher B, Winfrey S, et al. (2006) Cross-clade
recognition and neutralization by the V3 region from clade C human
immunodeficiency virus-1 envelope. Vaccine 24: 4995–5002.
34. Laird ME, Igarashi T, Martin MA, Desrosiers RC (2008) Importance of the V1/
V2 loop region of simian-human immunodeficiency virus envelope glycoprotein
gp120 in determining the strain specificity of the neutralizing antibody response.
J Virol 82: 11054–11065.
35. Derdeyn CA, Decker JM, Bibollet-Ruche F, Mokili JL, Muldoon M, et al. (2004)
Envelope-constrained neutralization-sensitive HIV-1 after heterosexual trans-
mission. Science 303: 2019–2022.
36. Teeraputon S, Louisirirojchanakul S, Auewarakul P (2005) N-linked glycosyl-
ation in C2 region of HIV-1 envelope reduces sensitivity to neutralizing
antibodies. Viral Immunol 18: 343–353.
37. Gnanakaran S, Lang D, Daniels M, Bhattacharya T, Derdeyn CA, et al. (2007)
Clade-specific differences between human immunodeficiency virus type 1 clades
B and C: diversity and correlations in C3-V4 regions of gp120. J Virol 81:
4886–4891.
38. Gaschen B, Taylor J, Yusim K, Foley B, Gao F, et al. (2002) Diversity
considerations in HIV-1 vaccine selection. Science 296: 2354–2360.
39. Rong R, Gnanakaran S, Decker JM, Bibollet-Ruche F, Taylor J, et al. (2007)
Unique mutational patterns in the envelope {alpha}2 amphipathic helix and
acquisition of length in gp120 hyper-variable domains are associated with
resistance to autologous neutralization of subtype C human immunodeficiency
virus type 1. J Virol 81: 5658–5668.
40. Leonard CK, Spellman MW, Riddle L, Harris RJ, Thomas JN, et al. (1990)
Assignment of intrachain disulfide bonds and characterization of potential
glycosylation sites of the type 1 recombinant human immunodeficiency virus
envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J Biol
Chem 265: 10373–10382.
41. Zhang M, Gaschen B, Blay W, Foley B, Haigwood N, et al. (2004) Tracking
global patterns of N-linked glycosylation site variation in highly variable viral
glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin.
Glycobiology 14: 1229–1246.
42. Zhu X, Borchers C, Bienstock RJ, Tomer KB (2000) Mass spectrometric
characterization of the glycosylation pattern of HIV-gp120 expressed in CHO
cells. Biochemistry 39: 11194–11204.
43. Tomaras GD, Yates NL, Liu P, Qin L, Fouda GG, et al. (2008) Initial B-cell
responses to transmitted human immunodeficiency virus type 1: virion-binding
immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41
antibodies with ineffective control of initial viremia. J Virol 82: 12449–12463.
44. van Loggerenberg F, Mlisana K, Williamson C, Auld SC, Morris L, et al. (2008)
Establishing a cohort at high risk of HIV infection in South Africa: challenges
and experiences of the CAPRISA 002 acute infection study. PLoS ONE 3:
e1954. doi: 10.1371/journal.pone.0001954.
45. Abrahams MR, Anderson JA, Giorgi EE, Seoighe C, Mlisana K, et al. (2009)
Quantitating the multiplicity of infection with HIV-1 subtype C reveals a non-
Poisson distribution of transmitted variants. J Virol 83: 3556–3567.
46. Salazar-Gonzalez JF, Bailes E, Pham KT, Salazar MG, Guffey MB, et al. (2008)
Deciphering human immunodeficiency virus type 1 transmission and early
envelope diversification by single-genome amplification and sequencing. J Virol
82: 3952–3970.
47. Tamura K, Dudley J, Nei M, Kumar S (2007) MEGA4: Molecular Evolutionary
Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 24: 1596–1599.
48. Gao F, Morrison SG, Robertson DL, Thornton CL, Craig S, et al. (1996)
Molecular cloning and analysis of functional envelope genes from human
immunodeficiency virus type 1 sequence subtypes A through G. The WHO and
NIAID Networks for HIV Isolation and Characterization. J Virol 70:
1651–1667.
49. Gray ES, Meyers T, Gray G, Montefiori DC, Morris L (2006) Insensitivity of
paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal
antibodies raised against subtype B. PLoS Med 3: e255. doi: 10.1371/journal.
pmed.0030255.
50. Montefiori D (2004) Evaluating neutralizing antibodies againts HIV, SIV and
SHIV in luciferase reporter gene assays. In: J. E. Coligan AMK, D. H. Margulies,
E.M.Shevach,W.Strober,and R.Coico,eds. CurrentProtocolsinImmunology.
New YorkNY: John Wiley & Sons. pp 12.11.11–12.11.15.
51. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, et al. (2008)
Identification and characterization of transmitted and early founder virus
envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A 105:
7552–7557.
52. Huang CC, Tang M, Zhang MY, Majeed S, Montabana E, et al. (2005)
Structure of a V3-containing HIV-1 gp120 core. Science 310: 1025–1028.
Neutralization Escape in HIV-1 Subtype C
PLoS Pathogens | www.plospathogens.org 13 September 2009 | Volume 5 | Issue 9 | e1000598